These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 35652700)

  • 1. Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database.
    Narita Y; Funatogawa T; Mii K; Adachi H; Tamura A; Yamakido S
    Mod Rheumatol; 2023 Apr; 33(3):525-532. PubMed ID: 35652700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study.
    Li Q; Wallace L; Patnaik P; Alves M; Gahlemann M; Kohlbrenner V; Raabe C; Wang JR; Garry EM
    Rheumatology (Oxford); 2021 Apr; 60(4):1915-1925. PubMed ID: 33155024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab treatment for systemic sclerosis-associated interstitial lung disease: a case series of 13 patients.
    Morgan K; Woollard C; Beinart D; Host LV; Roddy J
    Intern Med J; 2023 Jul; 53(7):1147-1153. PubMed ID: 35670218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of interstitial lung disease at initial visit may predict a favorable outcome for Japanese patients with systemic sclerosis with anti-topoisomerase I antibody.
    Hamaguchi Y; Yoshimura Y; Horii M; Fushida N; Kitano T; Sawada K; Oishi K; Maeda S; Watanabe S; Matsushita T
    J Dermatol; 2024 Jan; 51(1):62-69. PubMed ID: 37864453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should we use nintedanib as early therapy in patients with SSc-ILD?
    Zanatta E; Moccaldi B; Szucs G; Spagnolo P
    Autoimmun Rev; 2024 Jan; 23(1):103463. PubMed ID: 37844857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.
    Raghu G; Montesi SB; Silver RM; Hossain T; Macrea M; Herman D; Barnes H; Adegunsoye A; Azuma A; Chung L; Gardner GC; Highland KB; Hudson M; Kaner RJ; Kolb M; Scholand MB; Steen V; Thomson CC; Volkmann ER; Wigley FM; Burlile D; Kemper KA; Knight SL; Ghazipura M
    Am J Respir Crit Care Med; 2024 Jan; 209(2):137-152. PubMed ID: 37772985
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis.
    Kreuter M; Bonella F; Blank N; Riemekasten G; Müller-Ladner U; Henes J; Siegert E; Günther C; Kötter I; Pfeiffer C; Schmalzing M; Zeidler G; Korsten P; Susok L; Juche A; Worm M; Jandova I; Ehrchen J; Sunderkötter C; Keyßer G; Ramming A; Schmeiser T; Kreuter A; Kuhr K; Lorenz HM; Moinzadeh P; Hunzelmann N
    Rheumatology (Oxford); 2023 Sep; 62(9):3067-3074. PubMed ID: 36708008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
    Macrea M; Ghazipura M; Herman D; Barnes H; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
    Ann Am Thorac Soc; 2024 Feb; 21(2):317-327. PubMed ID: 37772987
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of tocilizumab in Japanese patients with systemic sclerosis and associated interstitial lung disease: A subgroup analysis of a global, randomised, controlled Phase 3 trial.
    Kuwana M; Takehara K; Tanaka Y; Yamashita K; Katsumata K; Takata M; Shima Y
    Mod Rheumatol; 2024 Mar; 34(3):530-540. PubMed ID: 37436828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years.
    Campochiaro C; Allanore Y
    Arthritis Res Ther; 2021 Jun; 23(1):155. PubMed ID: 34074331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Description of a single centre cohort of patients with systemic sclerosis from the University Hospital of Buenos Aires and factors associated with lung function deterioration. A retrospective study.
    Enghelmayer JI; López Meiller MJ; Vallejos A; Felder F; Pertuz MM; Arias T; Legarreta CG; Acuña S; Leiva S; Barrios V; Dubinsky D
    Reumatol Clin (Engl Ed); 2023; 19(7):351-357. PubMed ID: 37661112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2023 Brazilian Society of Rheumatology guidelines for the treatment of systemic sclerosis.
    Kayser C; de Oliveira Delgado SM; Zimmermann AF; Horimoto AMC; Del Rio APT; de Souza Müller C; Camargo CZ; Lupo CM; de Moraes DA; Do Rosário E Souza EJ; Santos FPST; Sekiyama JY; Lonzetti LS; de Oliveira Martins LV; Bezerra MC; Bredemeier M; Oliveira MC; da Fonseca Salgado MC; Miossi R; de Araújo Fontenele SM; Hax V; Dantas AT; Sampaio-Barros PD
    Adv Rheumatol; 2024 Jul; 64(1):52. PubMed ID: 38987832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis of patients with systemic sclerosis-related interstitial lung disease on the lung transplant waiting list: a retrospective study.
    Nakayama Y; Nakashima R; Handa T; Ohsumi A; Yamada Y; Nakajima D; Yutaka Y; Tanaka S; Hamada S; Ikezoe K; Tanizawa K; Shirakashi M; Hiwa R; Tsuji H; Kitagori K; Akizuki S; Yoshifuji H; Date H; Morinobu A
    Sci Rep; 2023 Jun; 13(1):10150. PubMed ID: 37349495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis.
    McMahan ZH; Volkmann ER
    Expert Opin Pharmacother; 2020 Nov; 21(16):2041-2056. PubMed ID: 32674612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comment on: Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis.
    Moran-Mendoza O; Al-Jarallah A; Alqahtani S; Paredes C
    Rheumatology (Oxford); 2023 Dec; 62(12):e349-e350. PubMed ID: 37369016
    [No Abstract]   [Full Text] [Related]  

  • 16. Summary for Clinicians: Clinical Practice Guideline for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations.
    Hossain T; Montesi SB; Volkmann ER; Thomson CC; Ruminjo JK; Silver RM; Ghazipura M; Raghu G
    Ann Am Thorac Soc; 2024 Jan; 21(1):12-16. PubMed ID: 37856309
    [No Abstract]   [Full Text] [Related]  

  • 17. Disease-modifying anti-rheumatic drug selection in Japanese patients with rheumatoid arthritis treated with biologics or JAK inhibitors without methotrexate: A retrospective hospital-based administrative claims database study.
    Miyakawa N; Tsuritani K; Teixeira BC; Fujio K
    Mod Rheumatol; 2024 Mar; ():. PubMed ID: 38450776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosis.
    Velauthapillai A; Bootsma MFR; Bruni C; Bergmann C; Matucci-Cerinic M; Launay D; Riemekastan G; Garzanova L; Airò P; Rezus E; da Silva JAP; Del Galdo F; Hunzelmann N; Chung LS; Krasowska D; Distler O; van den Ende CHM; Vonk MC;
    Rheumatology (Oxford); 2024 Jul; ():. PubMed ID: 39037917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comment on: Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis-caution is key in interpreting retrospective data: Reply.
    Kreuter M; Bonella F; Moinzadeh P; Hunzelmann N
    Rheumatology (Oxford); 2023 Dec; 62(12):e351-e352. PubMed ID: 37369015
    [No Abstract]   [Full Text] [Related]  

  • 20. Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?
    Andréasson K; Hamberg V; Wigén J; Westergren-Thorsson G
    Nat Rev Rheumatol; 2023 Oct; 19(10):675. PubMed ID: 37605003
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.